Description
Buy Saxenda (Liraglutide) Online – The Established Daily Weight Loss Injection
What is Saxenda?
Saxenda is a prescription-only medication developed by Novo Nordisk that has been used for weight management for several years. It contains liraglutide, a human glucagon-like peptide-1 (GLP-1) analogue with 97% amino acid sequence homology to endogenous human GLP-1 . As a GLP-1 receptor agonist, Saxenda works by binding to and activating GLP-1 receptors in the brain, pancreas, and gastrointestinal tract. This unique mechanism reduces appetite, promotes satiety, enhances glucose-dependent insulin secretion, and delays gastric emptying. Unlike other GLP-1 agonists that require weekly injections, Saxenda is administered daily, providing consistent appetite control throughout the day.
How Does Saxenda Work?
Saxenda’s mechanism of action is scientifically proven. The active ingredient, liraglutide, mimics the GLP-1 hormone naturally produced in the gut. GLP-1 is a physiological regulator of appetite and food intake . The official Saxenda website explains that the medication addresses one of the body’s natural responses to weight loss by regulating appetite, which can lead to eating fewer calories and losing weight.
In animal studies, peripheral administration of liraglutide led to uptake in specific brain regions involved in regulation of appetite, where liraglutide, via specific activation of the GLP-1 receptor, increased key satiety and decreased key hunger signals . This activation of the GLP-1 receptor works through multiple pathways: it reduces hunger signals in the hypothalamus, slows gastric emptying to promote prolonged fullness, and increases insulin secretion while suppressing glucagon release . These combined effects lead to significant and sustainable weight loss when used alongside a reduced-calorie diet and increased physical activity.
Clinical Efficacy: Proven Weight Loss Results
Saxenda has demonstrated consistent weight loss results in clinical trials and real-world studies. The manufacturer’s clinical trial of 3,731 adults with a BMI of 27-29.9 with at least one weight-related condition, or BMI of at least 30, showed that 85% of people taking Saxenda lost some weight. Specifically, 62% of patients achieved at least 5% weight loss, 34% achieved at least 10% weight loss, and 13% achieved at least 20% weight loss . The average weight loss in this study was approximately 5% to 7.4% of initial body weight after 56 weeks .
Real-world evidence further supports Saxenda’s effectiveness. A study of 50 patients with obesity and prediabetes awaiting bariatric surgery found that liraglutide 3.0 mg produced a consistent and statistically significant reduction in weight across all time intervals. At 52 weeks, average weight loss was 14 kg, with 85.7% of patients achieving at least 5% weight loss and 33.3% achieving at least 10% weight loss . The medication was well-tolerated, with only 10% discontinuing due to tolerability issues .
Long-term data demonstrates sustained weight loss. In a 3-year study of 2,254 adults with prediabetes and BMI ≥30 or ≥27 with one or more weight-related conditions, 56% achieved significant weight loss at year 1, and approximately half of these patients maintained weight loss at 3 years when taking Saxenda added to a reduced-calorie meal plan and increased physical activity .
For adolescents aged 12 to 17 years with obesity, a 1-year study showed that teens treated with Saxenda lowered their BMI-for-age by 0.23, compared to no reduction in the placebo group, when combined with healthy nutrition and physical activity counseling.
Comparison with Other Treatments
When compared to other weight loss medications, Saxenda offers a well-established safety profile and daily administration. A meta-analysis of multiple clinical trials found that semaglutide 2.4 mg led to a weight loss of 12.5 kg, whereas liraglutide 3 mg resulted in 5.2 kg weight loss over 20 to 68 weeks . This suggests that while Saxenda is effective, other once-weekly options may offer greater weight loss. However, Saxenda remains a valuable option for patients who prefer daily administration, have not tolerated weekly injections, or require a more gradual titration schedule. Saxenda is the only GLP-1 agonist FDA-approved for weight management in adolescents aged 12-17, offering a unique advantage for younger patients.
Safety Information
Boxed Warning
Saxenda carries a Boxed Warning regarding the risk of thyroid C-cell tumors. In rodent studies, liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors. The human relevance of this finding has not been determined . Saxenda is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Most Common Side Effects
Clinical studies have shown that the most common adverse reactions (reported in ≥5% of patients) include nausea, vomiting, diarrhoea, constipation, abdominal pain, and injection site reactions. Nausea is the most common side effect, especially during dose escalation . Most gastrointestinal side effects occur when increasing the dose and decrease over time as the body adjusts. The gradual titration schedule is designed to minimize these effects .
Serious Warnings and Precautions
Saxenda has been associated with the following serious risks: Acute Pancreatitis (discontinue immediately if suspected), Hypoglycemia (risk increases when used with insulin or sulfonylureas), Hypersensitivity Reactions, Acute Kidney Injury (due to volume depletion), and Acute Gallbladder Disease .
Eligibility and Indications
Saxenda is indicated for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in :
- Adults with an initial BMI of ≥ 30 kg/m² (obesity), or
- Adults with an initial BMI of ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity, including:
- Adolescents aged 12-17 years with a body weight above 132 pounds (60 kg) and obesity
- Age 18 years or over for adults
Dosage and Administration
Saxenda is administered as a once-daily subcutaneous injection using a pre-filled pen. The dosing schedule follows a structured titration approach to minimize gastrointestinal side effects:
| Week | Daily Dose |
|---|---|
| 1 | 0.6 mg |
| 2 | 1.2 mg |
| 3 | 1.8 mg |
| 4 | 2.4 mg |
| 5 and onward | 3 mg (maintenance dose) |
Important administration guidelines :
- Inject once daily at any time of day, without regard to meals
- Inject subcutaneously in the abdomen, thigh, or upper arm
- Rotate injection sites within the same region
- If a dose is missed, resume the once-daily regimen with the next scheduled dose—do not take an extra dose
- If more than 3 days have elapsed since the last dose, reinitiate at 0.6 mg and follow the escalation schedule
Treatment monitoring :
- For adults: Evaluate weight loss at 16 weeks; discontinue if patient has not lost at least 4% of baseline body weight
- For pediatric patients: Evaluate BMI reduction after 12 weeks on maintenance dose; discontinue if BMI reduction is less than 1%
- The starting pen should last 17 days during titration; once at 3 mg maintenance, each pen lasts 6 days
Saxenda Treatment Pricing (UK)
Saxenda is available through private prescription in the UK. Pricing is typically per pen or per pack:
| Pack Size | Typical Private Price |
|---|---|
| 1 pen | £69 |
| 2 pens | £135.99 |
| 5 pens | £334.99 – £375.00 |
| 10 pens | £750.00 |
Prices are indicative and may vary by provider. All prices typically include full clinical assessment and ongoing clinical support . At the starting dose (0.6mg), one pen lasts 17 days. Once at the maintenance dose (3mg), a pack of 5 pens lasts 30 days .
Frequently Asked Questions (FAQs)
1. How much weight can I expect to lose on Saxenda?
Based on clinical trial results, patients on Saxenda lose an average of 5–10% of their body weight over 56 weeks. In one study, 85% of people taking Saxenda lost some weight, with 62% achieving at least 5% weight loss and 34% achieving at least 10% weight loss . Real-world data showed average weight loss of 14 kg at 52 weeks .
2. How quickly does Saxenda start working?
Weight loss is typically gradual, with the most significant results seen after 56 weeks . However, many patients report reduced appetite within the first few weeks of starting treatment. The gradual dose titration helps the body adjust while beginning to see early effects.
3. What is the difference between Saxenda and Ozempic?
Both are GLP-1 receptor agonists, but they are approved for different indications. Saxenda is FDA-approved for weight management, while Ozempic is approved for type 2 diabetes. Ozempic contains semaglutide and is administered once weekly, while Saxenda contains liraglutide and is administered daily. Studies suggest Ozempic may lead to greater weight loss than Saxenda.
4. What are the most common side effects of Saxenda?
The most common side effects are gastrointestinal and include nausea, vomiting, diarrhoea, constipation, and abdominal pain. Nausea is especially common during the dose escalation phase . Most side effects decrease over time as your body adjusts to the medication.
5. Is Saxenda safe for long-term use?
Saxenda has been studied extensively with follow-up periods of up to 3 years showing sustained weight loss . The safety profile is well-established, with the main concern being the Boxed Warning regarding thyroid C-cell tumors, a risk primarily observed in animal studies.
6. Can Saxenda be used with other medications?
Saxenda may interact with other medications. Concomitant use with insulin or sulfonylureas may increase the risk of hypoglycemia. Patients should discuss all medications with their healthcare provider.
7. What happens if I miss a dose of Saxenda?
If you miss a dose, resume the once-daily regimen with your next scheduled dose. Do not take an extra dose or increase the dose to make up for the missed dose. If more than 3 days have elapsed since your last dose, reinitiate at 0.6 mg and follow the dose escalation schedule .
8. Who is eligible for Saxenda treatment?
Saxenda is indicated for adults with a BMI of 30 kg/m² or above (obese), or a BMI of 27 kg/m² or above (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or cardiovascular disease. It is also approved for adolescents aged 12-17 with obesity .
9. Is Saxenda covered by the NHS?
Saxenda is available through the NHS under NICE guidance for patients meeting specific criteria, including a BMI of 35 or above and at least one weight-related comorbidity. However, access is typically through specialist weight management services and availability may be limited.
10. Can I stop taking Saxenda once I reach my weight loss goal?
Stopping Saxenda may lead to weight regain. The 3-year clinical study showed that patients who continued treatment maintained weight loss, while those who discontinued experienced weight regain. Discuss maintenance strategies with your healthcare provider to create a plan for long-term weight management. Discontinue Saxenda if you have not lost at least 4% of baseline body weight at 16 weeks, as it is unlikely you will achieve clinically meaningful weight loss with continued treatment .
References and Additional Resources
For more information about Saxenda, consult these reputable sources:
- Saxenda Official Website
- FDA Prescribing Information
- Drugs.com Saxenda Dosage Guide
- NHS Guide to Liraglutide
- Novo Nordisk Official Website
Reviews
There are no reviews yet.